Projects / Programmes source: ARIS

Pharmacology and pharmacogenomics

Research activity

Code Science Field Subfield
3.03.00  Medical sciences  Neurobiology   
1.05.00  Natural sciences and mathematics  Biochemistry and molecular biology   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 

Code Science Field
3.01  Medical and Health Sciences  Basic medicine 
1.06  Natural Sciences  Biological sciences 
pharmacology, drug targets, medicines, pharmacogenomics,
Evaluation (rules)
source: COBISS
Data for the last 5 years (citations for the last 10 years) on September 23, 2023; A3 for period 2017-2021
Data for ARIS tenders ( 04.04.2019 – Programme tender , archive )
Database Linked records Citations Pure citations Average pure citations
WoS  518  16,903  15,802  30.51 
Scopus  504  18,700  17,497  34.72 
Researchers (33)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  33666  PhD Vojko Berce  Medical sciences  Researcher  2018 - 2021  216 
2.  55276  Petra Berlak    Technical associate  2021 
3.  29835  PhD Tomaž Budefeld  Medical sciences  Researcher  2019 - 2023  89 
4.  36896  Barbara Buh    Technical associate  2018 
5.  36818  PhD Helena Sabina Čelešnik  Natural sciences and mathematics  Researcher  2018 - 2021  61 
6.  10990  PhD Katarina Černe  Medical sciences  Researcher  2018 - 2023  102 
7.  26446  PhD Barbara Dariš  Natural sciences and mathematics  Researcher  2018 - 2023  51 
8.  17939  Nevenka Dolžan    Technical associate  2018 - 2023 
9.  08313  PhD Ilonka Ferjan  Medical sciences  Researcher  2018 - 2023  73 
10.  22621  PhD Polonca Ferk  Medical sciences  Researcher  2018  139 
11.  26010  PhD Boris Gole  Natural sciences and mathematics  Researcher  2018 - 2021  61 
12.  33268  PhD Mario Gorenjak  Natural sciences and mathematics  Researcher  2019 - 2021  151 
13.  34478  PhD Larisa Goričan  Medical sciences  Researcher  2018 - 2021  27 
14.  17937  Matjaž Hrovat    Technical associate  2018 - 2023 
15.  17940  Marjetka Jakomin    Technical associate  2018 - 2023 
16.  39240  PhD Gregor Jezernik  Medical sciences  Researcher  2018 - 2021  32 
17.  35232  PhD Staša Jurgec  Medical sciences  Researcher  2018 - 2023  19 
18.  17935  Jožica Košir    Technical associate  2018 - 2023 
19.  01846  PhD Gordana Koželj  Medical sciences  Technical associate  2018 - 2020  106 
20.  56728  Andreja Kralj    Technical associate  2022 - 2023 
21.  17936  Mojca Kranjec    Technical associate  2018 - 2023 
22.  55936  Martina Krušič  Medical sciences  Junior researcher  2021 
23.  08095  PhD Mojca Kržan  Medical sciences  Head  2018 - 2023  268 
24.  15536  PhD Metoda Lipnik Štangelj  Medical sciences  Researcher  2018 - 2023  205 
25.  26511  PhD Mitja Martelanc  Natural sciences and mathematics  Researcher  2018  68 
26.  16340  PhD Uroš Potočnik  Medical sciences  Researcher  2018 - 2021  604 
27.  28417  PhD Katja Repnik  Medical sciences  Researcher  2018 - 2019  132 
28.  53471  Vesna Sočan  Medical sciences  Junior researcher  2019 - 2023 
29.  29750  PhD Janez Šimenc  Medical sciences  Researcher  2018 - 2020  24 
30.  10974  PhD Irena Zajc  Natural sciences and mathematics  Researcher  2021 - 2023  134 
31.  22072  PhD Tomaž Zupanc  Medical sciences  Researcher  2018 - 2023  184 
32.  35388  PhD Mateja Zupin  Medical sciences  Researcher  2019 - 2021  23 
33.  29416  PhD Lovro Žiberna  Medical sciences  Researcher  2018 - 2023  235 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0381  University of Ljubljana, Faculty of Medicine  Ljubljana  1627066  45,607 
2.  2334  University of Maribor, Faculty of Medicine  Maribor  5089638048  16,086 
Pharmacology Pharmacology is a scientific discipline dealing with the research of potential and established drug action on biological systems. Future of pharmacology research lies in identifying new drugs, which can target novel proteins involved in the pathogenesis of certain diseases. On the other hand, also the drug effects (beneficial, adverse) of the established and approved drugs must be investigated in detail for the potential drug-repurposing or safety issues. Drug targets can be changed due to various reasons, such as senescence, oxidative stress, hypoxia, chronic disease progression, and chronic exposure to drugs and environmental toxins. Changes in drug targets can lead to alteration of ligand-target interaction. The aim of our research is to investigate the role of drugs on i) release and uptake of mediators, neurotransmiters and other ligans; ii) to characterize the interaction between ligand and drugs, and the role of hydrogen bonding; iii) effects of drugs in proinflammatory and antiinflammatory processes, in oxidative stress and cell death (apoptosis, necroptosis, necrosis); iv) research oriented in pharmacological modulation of biomarkers in aging, degenerative diseases and cancer; v) drug-repurposing research oriented in the modulation of endogenous antioxidants in serum.  Pharmacogenomics The aim of our proposed pharmacogenomics studies is to describe molecular mechanisms contributing to non-response to biological drugs in chronic immune diseases and cancer and to identify molecular genetic markers that could predict treatment response and could be used for personalized/precision medicine. Initially, we will focus on anti-TNF therapy in patients with Crohn's disease (CD) and Rheumatoid artthrirtis (RA). Integration of genetic (NGS, genotyping), gene expression (RNAseq), proteomic, epigenetic (DNA and histone modification) and gene regulation (non-coding RNA profiling, splice variants) data with bioinformatic tools (gene ontology - GO) will ensure identification and description of biological pathways important in treatment response. Our study is fully feasible, as we have already developed a comprehensive biobank that includes one of the world's largest collections of combined DNA/RNA/protein samples for chronic immune diseases (600 Inflammatory bowel diseases, 300 RA, 200 Multiple sclerosis and 350 asthma) and cancers (breast cancer, head and neck cancer, colorectal cancer). Our biobank includes comprehensive clinical data, including treatment response. For example, part of our biobank represents RNA samples and response data from the subgroup of CD patients collected before and during anti-TNF treatment (weeks 0, 4, 12, 20, 30).  Interesting new findings are expected from the comparison between gene expression profiles obtained from patients on anti-TNF therapy representing TNF inhibition in vivo and RNA samples obtained from treated cell cultures and cell lines, representing inhibition in vitro.
Significance for science
Research programme P3-067 is interdisciplinary built. Both areas of basic pharmacology and pharmacogenomics belong to non-clinical (bio) medical research (translational area T2). As it is seen from the publications, we are cooperating with the basic (translational area T1) as well as clinical researchers (translational area T3). Links within and outside research groups enable not only the rapid development of the both scientific disciplines  but help in faster development of new drugs, biologics, new diagnostic tools and treatments, but also smoother transfer of results into clinical practice. The results of the research program will explain the effects and mechanisms of action of endogenous and exogenous substances investigated: neurotransmitters (eg. histamine), modulators (bilirubin, cytokines) and toxins (ethanol) on the human body in various physiological and pathophysiological conditions. Some of the results will show new applications of known pharmacologically active substances in clinical practice (anti-inflammatory drugs, drugs acting on the central nervous system). On the other hand, the obtained results could reveal pathways to new medicines development. The senescing society needs in particular drugs with nootropic action and short-acting hypnotics, which do not cause tolerance and dependence. Interdisciplinary integration of pharmacology and pharmacogenomics represents a new added value of research results in both areas. A significant part of pharmacological research is still focused on the study of sites of drug action in the central nervous system and drugs that affect the central nervous system (psychotropic, nootropic, hypnotics) and drugs or therapeutic procedures to prevent auto-oxidation and the consequent degeneration in the central nervous system and cardiovascular system, which is in line with European research priorities to overcome the burden of aging society and epidemic of dementia.
Significance for the country
A drug is a product used for the treatment, alleviation, prevention, or diagnosis of a disease. Rational use of drugs limits the outbreaks of certain diseases, improve survival and enhance the quality of life of patients with chronic diseases. Drugs, discovered and developed in the 20th century (antibiotics, heart failure drugs, anticancer drugs) significantly reduced the mortality and prolong the life period of people in the past century. In addition to that drugs represent the most affordable therapeutic approach in clinical medicine. Exploring the characteristics of existing and potential new medicines, their sites of action and effects that appear during treatment increases the knowledge of researchers who as university teaching stuff are obliged to share the knowledge about drugs to students of medicine, dentistry, pharmacy and health sciences. The broad knowledge of pharmacology make the researchers of this program also competent experts that participate in the evaluation procedures of drug quality, efficacy and safety at European Medicines Agency and Slovenian Medicines Agency.
Most important scientific results Interim report
Most important socioeconomically and culturally relevant results Interim report
Views history